Companies › GEn1E Lifesciences
1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GEn-1124 | – | Phase 2 | Respiratory Distress Syndrome, Acute | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05795465 | GEn-1124 | Phase 2 | Respiratory Distress Syndrome, Acute | Respiratory | Dec 2026 |
No annotated target.
–
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense ReCode Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.